Intrinsic and acquired resistance to cetuximab in colorectal cancer patients

被引：0
|
作者：
Bray, Steven M.
Lee, Jeeyun
Kim, Seung Tae
Ebert, Philip J.
Calley, John N.
Wulur, Isabella H.
Gopalappa, Thejaswini
Wong, Swee Seong
Qian, Hui-Rong
Ting, Jason C.
Liu, Jiangang
Willard, Melinda D.
Aggarwal, Amit
Novosiadly, Ruslan D.
Kim, Hee-Cheol
Reinhard, Christoph
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4104
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Cetuximab plus irinotecan in refractory colorectal cancer patients
    Delgao, Marian Gil
    Spano, Jean-Philippe
    Khayat, David
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (04) : 407 - 413
  • [42] CETUXIMAB AS MONOTHERAPY IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER
    Esther, Una Cidon
    Tamas, Hickish
    Pilar, Alonso
    ANNALS OF ONCOLOGY, 2014, 25
  • [43] Cetuximab-induced hypomagnesemia in patients with colorectal cancer
    Fakih, Marwan G.
    Wilding, Gregory
    Lombardo, Jeffrey
    CLINICAL COLORECTAL CANCER, 2006, 6 (02) : 152 - 156
  • [44] GC1118, a new anti-EGFR antibody overcome acquired resistance to cetuximab in colorectal cancer xenograft model
    Lee, Shi-Nai
    Cho, Hyun-Jung
    Lim, Yangmi
    Hur, Minkyu
    Lee, Eun Hee
    Lee, Jae-Chul
    Lee, Kyuhyun
    Kim, Sujeong
    Won, Jonghwa
    CANCER RESEARCH, 2016, 76
  • [45] Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
    Lucien Torlot
    Anna Jarzab
    Johanna Albert
    Ágnes Pók-Udvari
    Arndt Stahler
    Julian Walter Holch
    Marco Gerlinger
    Volker Heinemann
    Frederick Klauschen
    Thomas Kirchner
    Jörg Kumbrink
    Bernhard Küster
    Andreas Jung
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 669 - 682
  • [46] Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
    Torlot, Lucien
    Jarzab, Anna
    Albert, Johanna
    Pok-Udvari, Agnes
    Stahler, Arndt
    Holch, Julian Walter
    Gerlinger, Marco
    Heinemann, Volker
    Klauschen, Frederick
    Kirchner, Thomas
    Kumbrink, Joerg
    Kuester, Bernhard
    Jung, Andreas
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 669 - 682
  • [47] FAS/FAS ligand ratio:: A marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer
    Nadal, C
    Maurel, J
    Gallego, R
    Castells, A
    Longarón, R
    Marmol, M
    Sanz, S
    Molina, R
    Martin-Richard, M
    Gascón, P
    CLINICAL CANCER RESEARCH, 2005, 11 (13) : 4770 - 4774
  • [48] Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
    Napolitano, Stefania
    Martini, Giulia
    Rinaldi, Barbara
    Martinelli, Erika
    Donniacuo, Maria
    Berrino, Liberato
    Vitagliano, Donata
    Morgillo, Floriana
    Barra, Giusy
    De Palma, Raffaele
    Merolla, Francesco
    Ciardiello, Fortunato
    Troiani, Teresa
    CLINICAL CANCER RESEARCH, 2015, 21 (13) : 2975 - 2983
  • [49] eOvercoming cetuximab resistance in colorectal cancer through inhibition of HGF processing
    Jones, Vivian Truong
    Graves-Deal, Ramona
    Bogatcheva, Galina
    Cao, Zheng
    Higginbotham, James
    Harmych, Sarah
    Ayers, Gregory
    Ramirez, Marisol
    Liu, Qi
    Janetka, James
    Singh, Bhuminder
    CANCER RESEARCH, 2023, 83 (07)
  • [50] Metastatic Colorectal Cancer Cetuximab Resistance Can Be Conferred by Genetic Mechanisms
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (04) : 696 - 697
12345